SCHEMBL25504103

SCHEMBL25504103

CCN1CCC(C)(NC(=O)c2cncc(Cl)c2C)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RET P07949 4/20 0.43
MT-CO2 P00403 1/20 0.35
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
CCR3 P51677 1/20 0.34
HDAC3 O15379 2/20 0.33
HDAC4 P56524 2/20 0.33
HDAC1 Q13547 2/20 0.33
HDAC7 Q8WUI4 2/20 0.33
HDAC2 Q92769 2/20 0.33
HDAC10 Q969S8 2/20 0.33
HDAC11 Q96DB2 2/20 0.33
HDAC8 Q9BY41 2/20 0.33
HDAC6 Q9UBN7 2/20 0.33
HDAC9 Q9UKV0 2/20 0.33
HDAC5 Q9UQL6 2/20 0.33
MAPT P10636 2/20 0.33
OPRM1 P35372 2/20 0.33
OPRD1 P41143 2/20 0.33
OPRK1 P41145 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20069181 0.86 RET (0.43) RETMT-CO2HDAC3HDAC4HDAC1
SCHEMBL20147624 0.83 RET (0.41) RETMT-CO2USP30
SCHEMBL20205892 0.82 MT-CO2 (0.46) RETMT-CO2MEN1KMT2ACCR3
SCHEMBL20205893 0.82 RET (0.40) RETHDAC3HDAC4HDAC1HDAC7
SCHEMBL25504106 0.80 RET (0.45) RETCCR3HDAC3HDAC4HDAC1
SCHEMBL25504246 0.80 RET (0.43) RETCCR3MAPTOPRM1OPRD1
SCHEMBL21652015 0.78 CHRM5 (0.53) MT-CO2KMT2ACCR3MAPTALDH1A1
SCHEMBL21651934 0.77 GAA (0.44) RETMEN1KMT2ACCR3MAPT
SCHEMBL25504243 0.76 ACKR3 (0.45) RET
SCHEMBL20205890 0.75 MAPT (0.47) RETMEN1KMT2ACCR3MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11648243-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2023-05-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11648243-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, BRAF, RAF1 RET 1/4885MT-CO2 4624/4885MEN1 653/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.